Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection
10.3349/ymj.2020.61.9.826
- Author:
Eun Jin KIM
1
;
Sun Ha CHOI
;
Jae Seok PARK
;
Yong Shik KWON
;
Jaehee LEE
;
Yeonjae KIM
;
Shin Yup LEE
;
Eun Young CHOI
Author Information
1. Division of Pulmonary and Critical Care Medicine, Daegu Catholic University Medical Center, Daegu, Korea.
- Publication Type:Brief Communication
- From:Yonsei Medical Journal
2020;61(9):826-830
- CountryRepublic of Korea
- Language:English
-
Abstract:
We retrospectively reviewed patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections who wereadmitted to an intensive care unit in Daegu, South Korea. The outcomes of patients who did (cases) or did not (controls) receivedarunavir-cobicistat (800–150 mg) therapy were compared. Fourteen patients received darunavir-cobicistat treatment, and 96 receivedother antiviral therapy (controls). Overall, the darunavir-cobicistat group comprised patients with milder illness, and thecrude mortality rate of all patients in the darunavir-cobicistat group was lower than that in the controls [odds ratio (OR) 0.20, 95%confidence interval (CI) 0.04–0.89, p=0.035]. After 1:2 propensity-score matching, there were 14 patients in the darunavir-cobicistatgroup, and 28 patients in the controls. In propensity score-matched analysis, the darunavir-cobicistat group had lower mortalitythan the controls (OR 0.07, 95% CI 0.01–0.52, p=0.009). In conclusion, darunavir-cobicistat therapy was found to be associatedwith a significant survival benefit in critically ill patients with SARS-CoV-2 infection.
